Quarterly report July – September 2003
QUARTERLY REPORT july – september 2003
* Merck & Co., Inc. has decided to discontinue the development of
one compound in the collaboration. A second candidate compound continues
in preclinical development.
* Karo Bio and Bristol-Myers Squibb have published data in
support for the obesity project in the scientific journal P.N.A.S.
(Proceedings of the National Academy of Sciences of the United States of
America).
* A new project aiming at development of selective thyroid
hormone agonists for treatment of dyslipidemia (STADs) has been
launched.
* Net sales amounted to MSEK 10.5 (76.8).
* Cash flows from operating activities amounted to MSEK -38.2
(8.3).
* The loss for the period, including goodwill amortization,
decreased to MSEK 34.3 (37.4). Operating result excluding goodwill
amortization amounted to MSEK -35.2 (21.2).
* Cash and cash equivalents and short-term investments amounted
to MSEK 234.6 (235.2) at the end of the period.
* Loss per share for the period amounted to SEK 2.03 (2.92).
For further information, please contact
Björn Nilsson, President & CEO tel. +46 8 608 60 20,
Per Otteskog, Senior Vice President, tel. +46 8 608 60 18, or
Bertil Jungmar, Chief Financial Officer, tel. +46 8 608 60 52.
————————————————————
This information was brought to you by Waymaker https://www.waymaker.net
The following files are available for download:
https://www.waymaker.net/bitonline/2003/10/15/20031015BIT00110/wkr0001.doc The full report
https://www.waymaker.net/bitonline/2003/10/15/20031015BIT00110/wkr0002.pdf The full report